Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026

Olema Pharmaceuticals, Inc.

Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.
Cash and marketable securities $505.4M; raised $218.5M in public offering.
Phase 3 OPERA-01 top-line data expected fall 2026; Phase 1b/2 with Pfizer atirmociclib initiated.
OP-3136 initial clinical data expected Q2 2026; commercial launch prep for potential late 2027 approval.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Olema Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively.

Period: the fourth quarter and full year ended December 31, 2025
Net income: Net loss for the quarter and year ended December 31, 2025 was $46.1 million and $162.5 million, respectively
Result: reported results

Exact text from the filing

On March 16, 2026, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the year ended December 31, 2025.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-107154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.